LivingGLP1
Study S001642

Impact of Exenatide on Cardiovascular Exercise Performance in Type 2 Diabetes

ClinicalTrials.gov record

Registration

Registration
NCT01364584
Acronym
Exenatide
Study type
INTERVENTIONAL
Allocation
RANDOMIZED
Masking
DOUBLE
Status
COMPLETED
Enrollment
23
Start
2010-10
Primary completion
2014-12
Lead sponsor
University of Colorado, Denver
Conditions
Type 2 Diabetes
Interventions
DRUG:Exenatide; DRUG:Placebo
Results posted
TRUE

Registered primary outcomes

  • Peak Oxygen Consumption (VO2 Peak) [Baseline and 3 months]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.